Life Sciences Directory

Bionorica research GmbH in Innsbruck, Austria, is a wholly-owned subsidiary of Bionorica SE, Germany. Bionorica SE is one of the leading manufacturers of herbal medicinal products in the world.

We are Experts at Translating Complex Science Into the Real-World: bridge the gap between science and people, manufacturers and regulators. At BioSciPons we work at the interface of regulatory, medical affairs and communication. We are experts at translating complex science into precise and clear communication contents (e.g., Reports, Technical files, Investigator Brochures, Medical Manuscripts, Articles, Instructions for Use, User Manuals, Video Scripts, Posters,...). Our aim is to explain the relevance and ramifications of your medical device or your scientific findings, while maintaining regulatory correctness and scientific acumen. We want to bridge the gap between R&D, regulatory agencies, healthcare and users/consumers - hence our bridge as a logo. To cross this bridge two things are needed: a high level of communication, and a deep understanding of clinical science & regulations. As clinical scientists, we understand the details. As communicators, we can transform your complex clinical data and translate it into a consistent message, that can then be tailored to each target audience (e.g., regulators, peer-reviewers, board executives, users/consumers/patients). With our "outside-of-the-box" approach, we can foresight the gaps in your clinical data; and prepare your product for the "curve ahead". We not only want you to cross the bridge, but help you go forward on a straight highway. BioSciPons works from any starting point for a customised service. We personalise our services to fit the needs of each individual medical/biotechnology product through PhD knowledge.

Expertise: Digital Therapeutics, Artificial Intelligence and Machine Learning Software as Medical Device, Injectables/Implantable's Class III.

The Biosimilars Association Austria is the voluntary interest group of biosimilars suppliers and producers. Biosimilars are equivalent successor products to biopharmaceuticals that have been approved on the market for years and whose patent has expired, thus providing an affordable alternative to expensive therapies. Our goal is to provide patients with access to innovative biopharmaceutical drug therapies that are also affordable in the long term.

In Austria, biotechnology is one of the fastest developing future industries with high growth dynamics and international competitiveness. In order to better represent the interests of this dynamic future industry, BIOTECH AUSTRIA has been the specific interest group of the Austrian biotechnology industry with the overarching goals of BIOTECH AUSTRIA of the targeted bundling of the interests of the industry in order to appear with a weighty voice in politics and society.